surmount-1 tirzepatide weight loss nondiabetic Trial SURMOUNT 1 // Three-Year Obesty

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study

If youre looking for a more aggressive approach to weight loss and have the ability to tolerate potential side effects, tirzepatide may be the better option due to its higher weight loss potential

For example, healthcare systems will need to decide how, when and for what indications they will reimburse new weight-loss drugs

The exit-strategy question remains unanswered - and this study was not designed to answer it

Sattar N, McGuire DK, Pavo I, et al